Understand the source comparison
Adamax for Memory: Research Use Comparison
Adamax ADAMTS4 inhibition → perineuronal net preservation Extracellular matrix (chondroitin sulfate proteoglycans) 0.5–5 mg/kg daily, 14–28 days Preclinical (rodent LTP models, hippocampal slice cultures). Limited published human data Most mechanistically spec
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Adamax
- ADAMTS4 inhibition → perineuronal net preservation
- Extracellular matrix (chondroitin sulfate proteoglycans)
- 0.5–5 mg/kg daily, 14–28 days
- Preclinical (rodent LTP models, hippocampal slice cultures). Limited published human data
- Most mechanistically specific for synaptic scaffold preservation; requires rigorous synthesis quality; limited to research settings
- Noopept (N-phenylacetyl-L-prolylglycine ethyl ester)
- Modulates AMPA/NMDA receptor activity, increases BDNF
- Glutamatergic synapses
- 0.5–1 mg/kg daily
- Preclinical + small human trials showing cognitive improvements in mild cognitive impairment
- Broader mechanism, more published human data; over-the-counter availability raises purity concerns; no structural preservation component
- Semax (ACTH(4-10) analog)
- Increases BDNF, modulates neurotrophic signaling
- Neurotrophic pathways (TrkB receptors)
- 50–300 µg/kg daily
- Preclinical + Phase II trials in ischemic stroke recovery
- Strong neuroprotective profile; works through growth factor signaling, not structural preservation; well-tolerated in clinical studies
- Cerebrolysin (porcine brain peptide extract)
- Neurotrophic + neuroprotective effects via multiple peptide fractions
- Broad (BDNF, NGF pathways, excitotoxicity reduction)
- 2.5–5 mL IV daily, 10–20 sessions
- Meta-analyses show benefit in vascular dementia and traumatic brain injury
- Clinically used in multiple countries; complex mixture makes mechanistic study difficult; IV-only administration limits research accessibility
- Adamax for memory stands apart in this comparison because it targets the extracellular matrix rather than neurotransmitter systems or neurotrophic signaling. For researchers investigating synaptic stability, perineuronal net dynamics, or age-related memory decline driven by structural degradation, Adamax offers mechanistic specificity that nootropics and neurotrophic peptides cannot provide. The tradeoff is limited human data and a requirement for laboratory-grade synthesis. Adamax is not a supplement, and its use is confined to controlled research settings. Researchers comparing Adamax to compounds like Cerebrolysin or Dihexa should consider whether their experimental question centers on synaptic transmission (in which case neurotrophic or receptor-modulating agents are more appropriate) or synaptic structural integrity (where Adamax's ADAMTS4 inhibition is uniquely relevant).